Dr Neil Portman
Dr Neil Portman completed his PhD in the field of molecular cell biology at the University of Oxford, UK. He worked on the single-celled eukaryotic parasite Trypanosoma brucei, etiological agent of African sleeping sickness, with a particular focus on the cytoskeleton and flagellum. He moved to the University of Sydney in 2012 after being awarded a Vice Chancellor’s postdoctoral fellowship to continue his interest in the biology of the eukaryotic flagellum in another model of parasitic disease, the apicomplexan. After a short career break being a full-time dad, he joined the Connie Johnson Breast Cancer Research Group at the Garvan Institute of Medical Research where he is applying his background in molecular biology, genome editing and proteomics techniques to generate and interrogate models of endocrine resistant breast cancer with the aim of identifying novel therapeutic strategies to improve outcomes for patients with advanced breast cancer.
- 2012University of Sydney Vice Chancellor’s Postdoctoral Research Fellowship
- 2023Cancer communications (London, England)10.1002/cac2.12425
Triple combination targeting PI3K, ER, and CDK4/6 inhibits growth of ER-positive breast cancer resistant to fulvestrant and CDK4/6 or PI3K inhibitor.
Epigenetic Therapies and Biomarkers in Breast Cancer.
- 2021Frontiers in oncology10.3389/fonc.2021.777867
MDM2 as a Rational Target for Intervention in CDK4/6 Inhibitor Resistant, Hormone Receptor Positive Breast Cancer.
- 2021Cell reports10.1016/j.celrep.2021.109722
DNA methylation is required to maintain both DNA replication timing precision and 3D genome organization integrity.
- 2021Nature communications10.1038/s41467-021-25901-z
Publisher Correction: Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer.